Kytril (Granisetron)

Granisetron works by selectively blocking 5‑HT3 receptors located in the central nervous system and the gastrointestinal tract. By preventing serotonin from activating these receptors, it interrupts the neural pathway that triggers the vomiting reflex, thereby reducing nausea and vomiting.

The dose of Kytril is determined by the prescribing clinician based on the patient’s condition, type of chemotherapy or surgery, and individual response. The medication is administered intravenously, and the exact amount and timing are specified in the medical order.

Granisetron’s pregnancy category is listed as unknown, meaning safety has not been established. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies the potential risk, and it must be decided by the treating physician.

To order Kytril, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Kytril belongs to the 5‑HT3 receptor antagonist class, similar to ondansetron. Both drugs block serotonin receptors to control nausea, but granisetron has a longer half‑life, allowing less frequent dosing in some protocols. Choice between them often depends on physician preference, patient tolerance, and specific chemotherapy regimens.

Kytril should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If the product must be transported, maintain the cold‑chain conditions and keep it in its original packaging to preserve stability.

Kytril is given by intravenous injection. The solution can be administered directly or diluted in compatible IV fluids according to the prescriber’s instructions. Administration is typically performed by a qualified healthcare professional in a clinical setting.

Serious risks include QT interval prolongation, which can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and rare cases of serotonin syndrome. Patients should be monitored for signs of cardiac rhythm changes, hypersensitivity, or unexplained neurological symptoms during treatment.

Kytril should be avoided in patients with known hypersensitivity to granisetron or any component of the formulation. It is also contraindicated in individuals with a history of significant QT prolongation or those taking other medications that markedly increase the QT interval without appropriate monitoring.